Drug Resistance Missense Mutations in Cancer Are Subject to Evolutionary Constraints
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Drug Resistance Missense Mutations in Cancer Are Subject to Evolutionary Constraints
Authors
Keywords
-
Journal
PLoS One
Volume 8, Issue 12, Pages e82059
Publisher
Public Library of Science (PLoS)
Online
2013-12-21
DOI
10.1371/journal.pone.0082059
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, Gleevec™)
- (2016) Heiko Kuip Therapeutics and Clinical Risk Management
- Evolutionary foundations for cancer biology
- (2013) C. Athena Aktipis et al. Evolutionary Applications
- Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR
- (2013) Eamon M. Berge et al. Journal of Thoracic Oncology
- Impact of deleterious passenger mutations on cancer progression
- (2013) C. D. McFarland et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer
- (2013) Ali Bashashati et al. GENOME BIOLOGY
- Discriminative modelling of context-specific amino acid substitution probabilities
- (2012) Christof Angermüller et al. BIOINFORMATICS
- Domain enhanced lookup time accelerated BLAST
- (2012) Grzegorz M Boratyn et al. Biology Direct
- BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships
- (2012) J. S. Khorashad et al. BLOOD
- Evolutionary Approaches to Prolong Progression-Free Survival in Breast Cancer
- (2012) A. S. Silva et al. CANCER RESEARCH
- The real war on cancer: the evolutionary dynamics of cancer suppression
- (2012) Leonard Nunney Evolutionary Applications
- Cancer as a moving target: understanding the composition and rebound growth kinetics of recurrent tumors
- (2012) Jasmine Foo et al. Evolutionary Applications
- The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer
- (2012) Richard T. Lewis et al. JOURNAL OF MEDICINAL CHEMISTRY
- Cancer and Natural Selection
- (2012) Mike Fillon JNCI-Journal of the National Cancer Institute
- Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors
- (2012) Susumu Kobayashi et al. Journal of Thoracic Oncology
- Perspective: Finding cancer's first principles
- (2012) Robert Gatenby NATURE
- CDD: conserved domains and protein three-dimensional structure
- (2012) Aron Marchler-Bauer et al. NUCLEIC ACIDS RESEARCH
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA
- (2012) T. Forshew et al. Science Translational Medicine
- Evolution of the cancer genome
- (2012) Ondrej Podlaha et al. TRENDS IN GENETICS
- Evolutionary Pathways in BRCA1-Associated Breast Tumors
- (2012) Filipe C. Martins et al. Cancer Discovery
- Improving the prediction of the functional impact of cancer mutations by baseline tolerance transformation
- (2012) Abel Gonzalez-Perez et al. Genome Medicine
- CHASM and SNVBox: toolkit for detecting biologically important single nucleotide mutations in cancer
- (2011) Wing Chung Wong et al. BIOINFORMATICS
- BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
- (2011) S. Soverini et al. BLOOD
- The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile
- (2011) C. A. Eide et al. CANCER RESEARCH
- Network of Cancer Genes (NCG 3.0): integration and analysis of genetic and network properties of cancer genes
- (2011) M. D'Antonio et al. NUCLEIC ACIDS RESEARCH
- Fitness Conferred by BCR-ABL Kinase Domain Mutations Determines the Risk of Pre-Existing Resistance in Chronic Myeloid Leukemia
- (2011) Kevin Leder et al. PLoS One
- The Neutral Theory of Molecular Evolution in the Genomic Era
- (2010) Masatoshi Nei et al. Annual Review of Genomics and Human Genetics
- An Alignment Confidence Score Capturing Robustness to Guide Tree Uncertainty
- (2010) O. Penn et al. MOLECULAR BIOLOGY AND EVOLUTION
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ultradeep Sequencing of a Human Ultraconserved Region Reveals Somatic and Constitutional Genomic Instability
- (2010) Anna De Grassi et al. PLOS BIOLOGY
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- Combination Therapies against Chronic Myeloid Leukemia: Short-term versus Long-term Strategies
- (2009) N. L. Komarova et al. CANCER RESEARCH
- Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
- (2009) Pasi A. Jänne et al. NATURE REVIEWS DRUG DISCOVERY
- Sequence context-specific profiles for homology searching
- (2009) A. Biegert et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Prediction of Cancer Driver Mutations in Protein Kinases
- (2008) A. Torkamani et al. CANCER RESEARCH
- Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma
- (2008) J. Bean et al. CLINICAL CANCER RESEARCH
- Detecting Site-Specific Biochemical Constraints Through Substitution Mapping
- (2008) Julien Dutheil JOURNAL OF MOLECULAR EVOLUTION
- Natural selection: The evolution of cancer
- (2008) Patrick Goymer NATURE
- Activating mutations in ALK provide a therapeutic target in neuroblastoma
- (2008) Rani E. George et al. NATURE
- Oncogenic mutations of ALK kinase in neuroblastoma
- (2008) Yuyan Chen et al. NATURE
- Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
- (2008) Isabelle Janoueix-Lerosey et al. NATURE
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
- (2008) C.-H. Yun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now